• In April 2026, PROCEPT BioRobotics Corporation reported first-quarter 2026 results showing sales of US$83.13 million versus US$69.16 million a year earlier, alongside a wider net loss of US$31.64 million and basic loss per share of US$0.56.
• At the same time, the company reaffirmed its full-year 2026 outlook, including expected revenue of US$390 million to US$410 million and a net loss range of US$78.50 million to US$91.50 million, underlining management’s confidence in its growth plans despite ongoing losses.
• We’ll now examine how reaffirming a full-year revenue outlook of up to US$410 million could influence PROCEPT BioRobotics’ existing investment narrative.

Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT BioRobotics, you need to believe Aquablation can become a mainstream urology treatment while the company eventually narrows its losses. The reaffirmed 2026 revenue outlook suggests the near term growth catalyst remains intact, but the widening net loss keeps execution risk around profitability front and center. Based on this update, the core risk remains whether procedure volumes and system utilization can scale fast enough to justify ongoing operating and R&D spend.

The most relevant recent development here is management’s decision on 29 April 2026 to reaffirm full year 2026 guidance for US$390 million to US$410 million in revenue and a net loss of US$78.50 million to US$91.50 million. That stance, coming right after a quarter of higher sales but deeper losses, ties directly into the key catalyst of expanding Aquablation adoption while highlighting that sustained operating losses are still part of the near term story.

But against that reaffirmed growth outlook, investors should also be aware that...

PROCEPT BioRobotics' narrative projects $608.2 million revenue and $77.8 million earnings by 2029. This requires 23.6% yearly revenue growth and a $180.3 million earnings increase from -$102.5 million today.

Uncover how PROCEPT BioRobotics' forecasts yield a $30.44 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming about 24.7 percent annual revenue growth to roughly US$597 million by 2029, yet still saw prolonged losses and reimbursement pressure as reasons to expect a weaker outcome than consensus, showing just how differently you and other shareholders might weigh this new guidance and execution risk.

Explore 6 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth 18% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.